Overview
Joseph C. Murray, M.D., Ph.D. is an Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins in the Upper Aerodigestive Cancer Division (UAD). He is Co-Director of the Lung Cancer Precision Medicine Center of Excellence (PMCOE) and directs the UAD Immunotherapy Database. Dr. Murray received his undergraduate degree in Molecular Cell Biology from the University of California, Berkeley in 2003. After working in the biotechnology industry, he went on to receive his medical and graduate degree in Interdisciplinary Tumor Biology at Georgetown University School of Medicine in 2015. After completing internship and residency in the Osler Medical Residency Training Program at Johns Hopkins Hospital, he remained at Johns Hopkins to complete his fellowship in Medical Oncology in the Sidney Kimmel Comprehensive Cancer Center. Dr. Murray conducts translational research in cancer genomics, liquid biopsy, and immunology in non-small cell lung cancer. He also has expertise in antibody-based immunotherapy, molecular and cell biology, and bioinformatics. He integrates research through the Lung Cancer PMCOE and UAD Immunotherapy Database to conduct observational clinical studies in real-world populations of patients with thoracic cancer. He cares for patients primarily at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Bayview Medical Center.
Dr. Murray is rated as an Advanced provider by MediFind in the treatment of EGFR Positive Lung Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC).
His clinical research consists of co-authoring 45 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of EGFR Positive Lung Cancer.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, Baltimore, MD 21224
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
University Of Maryland Oncology Associates PA
Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.
Inova Health Care Services
Janakiraman Subramanian is an Oncologist and a Hematologist in Fairfax, Virginia. Dr. Subramanian is rated as a Distinguished provider by MediFind in the treatment of EGFR Positive Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Subramanian is currently accepting new patients.
Johns Hopkins Bayview Medical Center
Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- EGFR Positive Lung CancerDr. Murray isAdvanced. Learn about EGFR Positive Lung Cancer.
- Lung CancerDr. Murray isAdvanced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Pleuropulmonary BlastomaDr. Murray isAdvanced. Learn about Pleuropulmonary Blastoma.
- Small Cell Lung Cancer (SCLC)Dr. Murray isAdvanced. Learn about Small Cell Lung Cancer (SCLC).
- Experienced
- ALK-Positive Non-Small Cell Lung CancerDr. Murray isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- Brain TumorDr. Murray isExperienced. Learn about Brain Tumor.
- Gastroesophageal Junction CancerDr. Murray isExperienced. Learn about Gastroesophageal Junction Cancer.
- Large-Cell Lung CarcinomaDr. Murray isExperienced. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Murray isExperienced. Learn about Lung Adenocarcinoma.
- MelanomaDr. Murray isExperienced. Learn about Melanoma.